RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) (“Talecris”) today announced the pricing through a private placement of $600 million aggregate principal amount of 7.75% senior notes due 2016 (the “Notes”). The Notes were issued at price of 99.321% of par. Talecris intends to use the net proceeds from the offering to repay its First and Second Lien Term Loans, repay a portion of borrowings under its Revolving Credit Facility, extinguish certain interest rate swaps, and pay related fees and expenses. The offering is expected to close on or about October 21, 2009, subject to customary closing conditions.
